The study aims to evaluate the effectiveness of combining chemotherapy (CT) with targeted therapy (TT) as a first-line treatment for advanced biliary tract cancer (BTC) through a meta-analysis of randomized clinical trials (RCTs).
The results showed that the combination of CT and TT significantly improved the objective response rate (ORR) compared to CT alone, although there was no notable difference in progression-free survival (PFS) or overall survival (OS).
Specific findings indicated that patients receiving gemcitabine combined with oxaliplatin as CT alongside TT experienced better ORR and longer PFS compared to those on CT alone, particularly benefiting those with cholangiocarcinoma.